androgenic alopecia; androgenetic alopecia; male balding pattern
Jump to navigation
Jump to search
Introduction
also see alopecia &/or pattern alopecia
Epidemiology
- most common cause of alopecia in men
- 50% of men at age 50 years; 70% at age 70 years[6]
- can effect men or women
Pathology
- dihydrotestosterone promotes involution of hair follicles in genetically-prone men
- non-scarring alopecia[6]
Genetics
- generally inherited trait
- autosomal dominant with mixed penetrance
- homozygous mutations of WNT10A cause recessive odonto-onycho dysplasia & sparse scalp & body hair[4] (WNT signaling occurs normally in hair development & hair cycling)
Clinical manifestations
- men
- women
Complications
- cardiovascular risk factor[3], especially, baldness at the crown of the head[3]
Differential diagnosis
- alopecia areata is generally associated with an area of marked baldness[6]
- telogen effluvium is trigerred by a stressful event
- commonly seen in post-partum women[6]
Management
- men
- some men elect to forgo treatment
- topical minoxidil 5% BID
- best results with patients < 30 with < 5 years hair loss
- oral finasteride or dustateride
- women
- topical minoxidil 2% (Rogaine) BID
- spironolactone[6]
- surgical procedures
- hair transplant
- scalp reduction
- flaps
More general terms
References
- ↑ Hair Loss and Its Causes FamilyDoctor.org http://familydoctor.org/online/famdocen/home/men/general/081.html
- ↑ Wikipedia: Baldness http://en.wikipedia.org/wiki/Baldness
- ↑ 3.0 3.1 3.2 Tomohide Yamada, Kazuo Hara, Hitomi Umematsu, Takashi Kadowaki Male pattern baldness and its association with coronary heart disease: a meta-analysis. BMJ Open 2013;3:e002537 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23554099 <Internet> http://bmjopen.bmj.com/content/3/4/e002537
- ↑ 4.0 4.1 Heilmann S et al. Androgenetic alopecia: Identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol 2013 Jun; 133:1489. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23358095
- ↑ Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010 Jun;11(8):1295-304 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20426708
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 2018.
- ↑ Genetics Home Reference: Androgenetic alopecia http://ghr.nlm.nih.gov/condition/androgenetic-alopecia
- ↑ Feinstein RP, Khardori R Medscape: Androgenetic Alopecia http://emedicine.medscape.com/article/1070167-overview
- ↑ 9.0 9.1 DermNet NZ. Female pattern hair loss (images) http://www.dermnetnz.org/hair-nails-sweat/female-pattern-hairloss.html
- ↑ 10.0 10.1 DermNet NZ. Male pattern hair loss (images) http://www.dermnetnz.org/hair-nails-sweat/pattern-balding.html
- ↑ Gupta AK, Venkataraman M, Talukder M et al Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients. A Network Meta-analysis. JAMA Dermatol. Published online February 2, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35107565 https://jamanetwork.com/journals/jamadermatology/fullarticle/2788258
Huang KP, Senna MM. Hair Are the Rankings - 5-alpha Reductase Inhibitors and Minoxidil in Male Androgenetic Alopecia. JAMA Dermatol. Published online February 2, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35107586 https://jamanetwork.com/journals/jamadermatology/fullarticle/2788261